Literature DB >> 4976484

Prevention of Rh hemolytic disease.

W Pollack, J G Gorman, V J Freda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4976484

Source DB:  PubMed          Journal:  Prog Hematol        ISSN： 0079-6301


× No keyword cloud information.
  8 in total

Review 1.  Suppression of the immune response.

Authors:  J Bradley; C J Elson
Journal:  J Med Genet       Date:  1971-09       Impact factor: 6.318

2.  Immunosuppressive therapy in Rh-incompatible transfusion.

Authors:  J Eklund; H R Nevanlinna
Journal:  Br Med J       Date:  1971-09-11

3.  The multiple use of RhoGAM.

Authors:  L Keith; M Halloway; R C Stepto
Journal:  J Natl Med Assoc       Date:  1973-01       Impact factor: 1.798

4.  Rh hemolytic disease of the newborn: using incidence observations to evaluate the use of RH immune globulin.

Authors:  M M Adams; J S Marks; J Gustafson; G P Oakley
Journal:  Am J Public Health       Date:  1981-09       Impact factor: 9.308

5.  RhoGam--current status.

Authors:  K P Russell
Journal:  Calif Med       Date:  1970-12

6.  Primary immunization of Rh-negative volunteers.

Authors:  H H Gunson; F Stratton; D G Cooper; V I Rawlinson
Journal:  Br Med J       Date:  1970-03-07

7.  Crossmatch difficulties following the prophylactic use of Rh immune globulin.

Authors:  J Wright; J Freedman; F C Lim; M B Garvey
Journal:  Can Med Assoc J       Date:  1979-05-19       Impact factor: 8.262

8.  Immunoglobulin G-mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the fetus and newborn?

Authors:  Davor Brinc; Hoang Le-Tien; Andrew R Crow; Vinayakumar Siragam; John Freedman; Alan H Lazarus
Journal:  Immunology       Date:  2008-02-07       Impact factor: 7.397
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.